Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.
Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.
复制标题
磷酸化 eIF2 α 可预测三阴性乳腺癌患者的无病生存期
DOI:
10.1038/srep44674
复制
发表时间:
2017-03-15
影响因子:
4.6
通讯作者:
Wu J
中科院分区:
文献类型:
--
作者:
Guo L;Chi Y;Xue J;Ma L;Shao Z;Wu J
Phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α), which functions as a marker of endoplasmic reticulum stress, has been reported to be associated with patient prognosis in various cancers. However, little is known about the prognostic value of p-eIF2α in breast cancer, particularly in different breast cancer subtypes. An immunohistochemistry screen for p-eIF2α was performed using a tissue microarray containing 233 tumors and paired peritumoral tissues from female patients diagnosed with breast cancer. The staining results were scored semiquantitatively, and the p-eIF2α expression level in breast cancer and its potential prognostic value were investigated. In this retrospective cohort study, we found that p-eIF2α levels were significantly upregulated in breast cancer (P < 0.001). p-eIF2α level was negatively correlated with lymph node status (P = 0.039). Survival analysis by Kaplan–Meier estimation and Cox regression showed that p-eIF2α level was correlated with better disease free survival (P = 0.026) and served as an independent prognostic factor (P = 0.046) in patients with triple-negative breast cancer. Our study revealed that p-eIF2α was upregulated in breast cancer and represented a novel predictor of prognosis in patients with triple-negative subtype.